PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA)
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)66787-3
https://www.valueinhealthjournal.com/article/S1098-3015(10)66787-3/fulltext
Title :
PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66787-3&doi=10.1016/S1098-3015(10)66787-3
First page :
Section Title :
Open access? :
No
Section Order :
621